MedTrace Logo

A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension

NCT02059616 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2014-04-30

No results posted yet for this study

Summary

The purpose of this study is to explore the optimal dose of fixed-dose combination of candesartan cilexetil and amlodipine besylate by examining the safety and efficacy of the combination therapy compared to each of the monotherapy in patients with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

Amlodipine 5mg

Daily oral administration for 8 weeks

DRUG

Amlodipine 10mg

Daily oral administration for 8 weeks

DRUG

Candesartan Cilexetil 8mg

Daily oral administration for 8 weeks

DRUG

Candesartan cilexetil 16mg

Daily oral administration for 8 weeks

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • Seung-Jea Tahk · Ajou University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-06-30
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059616 on ClinicalTrials.gov